Research ArticleClinical Review

GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease

Leigh Morrison, Jonathan Gabison and Lauren Oshman
The Journal of the American Board of Family Medicine May 2024, 37 (3) 372-382; DOI: https://doi.org/10.3122/jabfm.2023.230455R1

References

  1. 1.↵
    Centers for Disease Control. Prevalence of both diagnosed and undiagnosed diabetes; 2022. Available at: https://www.cdc.gov/diabetes/data/statistics-report/index.html.
  2. 2.↵
    1. Raghavan S,
    2. Vassy JL,
    3. Ho Y,
    4. et al
    . Diabetes mellitus–related all‐cause and cardiovascular mortality in a national cohort of adults. JAHA 2019;8:e011295.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Centers for Disease Control. National diabetes statistics report 2020. CDC; 2020. Available at: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
  4. 4.↵
    1. Cameron NA,
    2. Petito LC,
    3. McCabe M,
    4. et al
    . Quantifying the sex‐race/ethnicity‐specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES. JAHA 2021;10:e018799.
    OpenUrl
  5. 5.↵
    1. Jacob S,
    2. Krentz AJ,
    3. Deanfield J,
    4. Rydén L
    . Evolution of type 2 diabetes management from a glucocentric approach to cardio-renal risk reduction: the new paradigm of care. Drugs 2021;81:1373–9.
    OpenUrl
  6. 6.↵
    American Diabetes Association. Standards of care in diabetes—2023 abridged for primary care providers. Clin Diabetes 2022;41:4–31.
    OpenUrlCrossRef
  7. 7.↵
    1. Gerstein HC,
    2. Miller ME,
    3. Byington RP
    , Action to Control Cardiovascular Risk in Diabetes Study Groupet al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Fonseca V,
    2. McDuffie R,
    3. Calles J
    , the ACCORD Study Groupet al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care. 2013;36:2162–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. ElSayed NA,
    2. Aleppo G,
    3. Aroda VR,
    4. et al
    . Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care 2022;46:S140–S157.
    OpenUrl
  10. 10.↵
    1. Cefalu WT,
    2. Kaul S,
    3. Gerstein HC,
    4. et al
    . Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a diabetes care editors’ expert forum. Dia Care 2018;41:14–31.
    OpenUrl
  11. 11.↵
    1. Shi Q,
    2. Nong K,
    3. Vandvik PO,
    4. et al
    . Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2023;381:e074068.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. D’Andrea E,
    2. Kesselheim AS,
    3. Franklin JM,
    4. Jung EH,
    5. Hey SP,
    6. Patorno E
    . Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 2020;19:154.
    OpenUrl
  13. 13.↵
    1. Heerspink HJL,
    2. Perkins BA,
    3. Fitchett DH,
    4. Husain M,
    5. Cherney DZI
    . Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation 2016;134:752–72.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Marx N,
    2. Husain M,
    3. Lehrke M,
    4. Verma S,
    5. Sattar N
    . GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 2022;146:1882–94.
    OpenUrl
  15. 15.↵
    1. O’Brien MJ,
    2. Karam SL,
    3. Wallia A,
    4. et al
    . Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes. JAMA Netw Open 2018;1:e186125.
    OpenUrl
  16. 16.↵
    1. Hinnen D
    . Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum 2017;30:202–10.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Nauck MA,
    2. Quast DR,
    3. Wefers J,
    4. Meier JJ
    . GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab 2020;46:101102.
    OpenUrl
  18. 18.↵
    1. Nauck MA,
    2. Müller TD
    . Incretin hormones and type 2 diabetes. Diabetologia 2023;66:1780–95. Published online July 11.
    OpenUrl
  19. 19.↵
    1. Sheahan KH,
    2. Wahlberg EA,
    3. Gilbert MP
    . An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J 2020;96:156–61.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Kristensen SL,
    2. Rørth R,
    3. Jhund PS,
    4. et al
    . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology 2019;7:776–85.
    OpenUrl
  21. 21.↵
    1. Iqbal J,
    2. Wu HX,
    3. Hu N,
    4. et al
    . Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials. Obesity Reviews 2022;23:e13435.
    OpenUrl
  22. 22.↵
    1. Bonora E,
    2. Frias JP,
    3. Tinahones FJ,
    4. et al
    . Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11. Diabetes Obesity Metabolism 2021;23:2242–50.
    OpenUrl
  23. 23.↵
    1. Sikirica MV,
    2. Martin AA,
    3. Wood R,
    4. Leith A,
    5. Piercy J,
    6. Higgins V
    . Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. DMSO 2017;10:403–12.
    OpenUrl
  24. 24.↵
    1. Gorgojo-Martínez JJ,
    2. Mezquita-Raya P,
    3. Carretero-Gómez J,
    4. et al
    . Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus.JCM 2022;12:145.
    OpenUrl
  25. 25.↵
    1. Davies MJ,
    2. Aroda VR,
    3. Collins BS,
    4. et al
    . Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45:2753–86.
    OpenUrlCrossRef
  26. 26.↵
    1. Bethel MA,
    2. Diaz R,
    3. Castellana N,
    4. Bhattacharya I,
    5. Gerstein HC,
    6. Lakshmanan MC
    . HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 2020;44:290–6.
    OpenUrl
  27. 27.↵
    1. Bain SC,
    2. Klufas MA,
    3. Ho A,
    4. Matthews DR
    . Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obesity Metabolism 2019;21:454–66.
    OpenUrl
  28. 28.↵
    1. De Block C,
    2. Bailey C,
    3. Wysham C,
    4. Hemmingway A,
    5. Allen SE,
    6. Peleshok J
    . Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obesity Metabolism 2023;25:3–17.
    OpenUrlCrossRef
  29. 29.↵
    1. Rizvi AA,
    2. Rizzo M
    . The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction. DMSO 2022;15:1023–30.
    OpenUrl
  30. 30.↵
    1. Garvey WT,
    2. Frias JP,
    3. Jastreboff AM,
    4. et al
    . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023;402:613–26.
    OpenUrl
  31. 31.↵
    1. Zurek AM,
    2. Yendapally R,
    3. Urteaga EM
    . A review of the efficacy and safety of sodium–glucose cotransporter 2 inhibitors: a focus on diabetic ketoacidosis. Diabetes Spectr 2017;30:137–42.
    OpenUrlFREE Full Text
  32. 32.↵
    1. McGuire DK,
    2. Shih WJ,
    3. Cosentino F,
    4. et al
    . Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–58.
    OpenUrl
  33. 33.↵
    1. ElSayed NA,
    2. Aleppo G,
    3. Aroda VR,
    4. et al
    . Chronic kidney disease and risk management: Standards of Care in Diabetes—2023. Diabetes Care 2023;46:S191–S202.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Vaduganathan M,
    2. Docherty KF,
    3. Claggett BL,
    4. et al
    . SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet 2022;400:757–67.
    OpenUrl
  35. 35.↵
    1. Arnott C,
    2. Li Q,
    3. Kang A,
    4. et al
    . Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. JAHA 2020;9:e014908.
    OpenUrlPubMed
  36. 36.↵
    1. Samson SL,
    2. Vellanki P,
    3. Blonde L,
    4. et al
    . American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 Update. Endocrine Practice 2023;29:305–40.
    OpenUrl
  37. 37.↵
    1. Engelhardt K,
    2. Ferguson M,
    3. Rosselli JL
    . Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother 2021;55:543–8.
    OpenUrl
  38. 38.↵
    FDA. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. FDA. Published online February 9, 2019. Accessed June 12, 2023. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes.
  39. 39.↵
    1. Blonde L,
    2. Umpierrez GE,
    3. Reddy SS,
    4. et al
    . American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocrine Practice 2022;28:923–1049.
    OpenUrlCrossRef
  40. 40.↵
    1. Meraz-Muñoz AY,
    2. Weinstein J,
    3. Wald R
    . eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360 2021;2:1042–7.
    OpenUrlFREE Full Text
  41. 41.↵
    1. DeSantis A
    . Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. UpToDate; 2023. Available at: https://www.uptodate.com/contents/sodium-glucose-cotransporter-2-inhibitors-for-the-treatment-of-hyperglycemia-in-type-2-diabetes-mellitus?csi=18d446c8-41ff-439f-ad89-01ecab3fe311&source=contentShare.
  42. 42.↵
    1. Yau K,
    2. Dharia A,
    3. Alrowiyti I,
    4. Cherney DZI
    . Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney International Reports 2022;7:1463–76.
    OpenUrl
  43. 43.↵
    1. Holman RR,
    2. Paul SK,
    3. Bethel MA,
    4. Matthews DR,
    5. Neil HAW
    . 10-year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med 2008;359:1577–89.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Masson W,
    2. Lavalle-Cobo A,
    3. Lobo M,
    4. Masson G,
    5. Molinero G
    . Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. European Journal of Preventive Cardiology 2021;28:69–75.
    OpenUrl
  45. 45.↵
    1. Heidenreich PA,
    2. Bozkurt B,
    3. Aguilar D,
    4. et al
    . 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–e1032.
    OpenUrlCrossRefPubMed
  46. 46.↵
    U.S. Food and Drug Administration. Highlights of prescribing information: Farxiga (dapagliflozin) tablets, for oral use. Medication Guide. May 2020. Accessed December 19, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s020lbl.pdf.
  47. 47.↵
    U.S. Food and Drug Administration. Highlights of prescribing information: Jardiance (empagliflozin tablets), for oral use. October 2022. Accessed December 19, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s033lbl.pdf.
  48. 48.↵
    Multiple Comparison SoF. Accessed September 21, 2023. Available at: https://matchit.magicevidence.org/230125dist-diabetes/#!/.
  49. 49.↵
    1. Li C,
    2. Luo J,
    3. Jiang M,
    4. Wang K
    . The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol 2022;13:838277.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Garber AJ,
    2. Handelsman Y,
    3. Grunberger G,
    4. et al
    . Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2020 executive summary. Endocrine Practice 2020;26:107–39.
    OpenUrl
  51. 51.↵
    1. Van Dril E,
    2. Allison M,
    3. Schumacher C
    . Deprescribing in type 2 diabetes and cardiovascular disease: recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American Heart Journal Plus: Cardiology Research and Practice 2022;17:100163.
    OpenUrl
  52. 52.↵
    American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes—2024. Diabetes Care 2023;47:S111–S125.
    OpenUrl
  53. 53.↵
    1. Choi JG,
    2. Winn AN,
    3. Skandari MR,
    4. et al
    . First-line therapy for type 2 diabetes with sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med 2022;175:1392–400.
    OpenUrl
  54. 54.↵
    1. Brennan Z
    . Novartis’ Sandoz settles with Novo Nordisk for 2024 launch of third Victoza generic. Endpoints News. Published online March 23, 2022. Available at: https://endpts.com/novartis-sandoz-settles-with-novo-nordisk-for-2024-launch-of-third-victoza-generic/.
  55. 55.↵
    1. Zoler M
    . FDA moves generic Dapagliflozin a step closer to US Sales. Medscape. Published online February 23, 2022. Available at: https://www.medscape.com/viewarticle/969050.
  56. 56.↵
    Medications Details | Mark Cuban Cost Plus Drug Company. Accessed September 21, 2023. Available at: https://costplusdrugs.com/medications/brenzavvy-20mg/index.html.
  57. 57.↵
    Michigan Collaborative for Type 2 Diabetes. Medication copay savings card programs reference guide. Published online March 10, 2023. Available at: https://www.mct2d.org/resource-library/commercial-copay-savings-cards-quick-reference-guide.
  58. 58.↵
    Michigan Collaborative for Type 2 Diabetes. Patient Assistance Program (PAP) Guide for patients with Medicare Part D and Uninsured. Published online March 10, 2023. Available at: https://www.mct2d.org/resource-library/pap-for-meds-medicare-part-d.
  59. 59.↵
    Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. Inflation Reduction Act Research Series: Medicare enrollees’ use and out-of-pocket expenditures for drugs selected for negotiation under the Medicare Drug Price Negotiation Program. (Fact Sheet No. HP-2023-21). September2023.
  60. 60.↵
    Research C for DE and Medications containing Semaglutide marketed for Type 2 diabetes or weight loss. FDA. Published online October 31, 2023. Accessed December 19, 2023. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords